WAM
FOLD

Wolverine Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Wolverine Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,200
Closed -$46K – 1514
2017
Q4 		$46K Sell
3,200
-5,800
-64% -$79.7K ﹤0.01% 1263
2017
Q3 		$135K Sell
9,000
-11,700
-57% -$155K ﹤0.01% 1052
2017
Q2 		$208K Buy
20,700
+3,100
+18% +$24.9K ﹤0.01% 946
2017
Q1 		$125K Buy
+17,600
New +$111K ﹤0.01% 918

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Wolverine Asset Management's FOLD Position: Q1 2026 in Review

Wolverine Asset Management increased its Amicus Therapeutics (FOLD) stake by 415% in Q1 2026, buying an estimated $1.45M and bringing the position to 125,265 shares worth $1.81M. The position accounts for 0.02% of the portfolio, ranked #602.

Wolverine Asset Management first reported a position in FOLD in Q4 2013 and has held it in 6 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Wolverine Asset Management held 125,265 shares of Amicus Therapeutics worth $1.81M as of Q1 2026.
  • Wolverine Asset Management bought 100,949 Amicus Therapeutics shares in Q1 2026, an estimated $1.45M.
  • Amicus Therapeutics made up 0.02% of Wolverine Asset Management's portfolio in Q1 2026, its #602 holding.
  • Wolverine Asset Management first reported a position in Amicus Therapeutics in Q4 2013 and has held it in 6 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.